BioSpace News Archive

Antares Pharma, Inc., a specialty pharmaceutical company, reported financial and operating results for the fourth quarter ended December 31, 2020 with record revenue of $44.1 million and net income of $51.4 million, or basic and diluted earnings per share of $0.31 and $0.30, respectively, which included a net tax benefit of $46.3 million.

Recently, CMAB Biopharma Inc’s partner QureBio Ltd has announced its innovative drug Q-1802 received United States Food and Drug Administration clearance for an Investigational New Drug application.

Fact.MR, a global research & consulting firm, in their updated edition of the report, indicated that the atrial fibrillation stroke treatment market is slated to expand as faster rate in 2021 and beyond.

Fact.MR, a global research & consulting firm, in their updated edition of the report, indicated that the nephrosclerosis treatment market is slated to record a moderate growth pace in 2021 and beyond.

Advancements in medical research has played an integral role in the growth of the global ubiquitin enzymes market.

The inclination towards improving the beauty and aesthetics of an individual has emerged as a lifestyle and is getting widely adopted worldwide.

SERB Specialty Pharmaceuticals, a leading European specialty pharmaceutical group focused on prescription medicines that address rare and life-threatening diseases, announced the acquisition of BTG Specialty Pharmaceuticals, a division of Boston Scientific that develops, manufactures, and commercializes antidotes and rescue medicines to treat patients with critical conditions.

Certification is deemed an international seal of approval and guarantees the highest quality standards for pharmaceutical excipients and other critical materials used by the pharmaceutical industry, such as DENARASE, a c-LEcta enzyme product that is used in the production of biopharmaceuticals and vaccines

Mind Cure Health Inc., a leader in developing technology to advance psychedelic-related treatments, is pleased to announce the completion of its initial strategic equity investment of equal to approximately 13% ownership in ATMA Journey Centers Inc.

Iktos announced today the application of Iktos Artificial Intelligence technology for de novo design to selected Pfizer small-molecule discovery programs.